MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. EBITDA 2011-2026 | ZOM
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -82.3 M | -49.5 M | -30.8 M | -21.5 M | -21.1 M | 17.1 M | -19 M | -16.4 M | -7.97 M | -54.5 K | -42.4 K | -77.5 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.1 M | -82.3 M | -19.3 M |
Quarterly EBITDA Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.1 M | -7.53 M | -64 M | - | -7.02 M | -24.7 M | -10.1 M | - | -5.75 M | -6.57 M | -7.35 M | - | -6.48 M | -5.72 M | -4.23 M | - | -6.35 M | -5.27 M | -3.81 M | - | -4.92 M | -5.22 M | -2.26 M | - | -2.57 M | -2.11 M | -11.4 M | - | -1.64 M | -3.94 M | -1.97 M | - | -2 M | -1.5 M | -1.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.5 M | -64 M | -7.86 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
8.47 M | $ 19.13 | -0.42 % | $ 122 M | USA |
 |
Bausch Health Companies
BHC
|
2.23 B | $ 5.35 | - | $ 1.95 B |  Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | - | - | $ 2.06 B |  France |
 |
Canopy Growth Corporation
CGC
|
-95.6 M | $ 1.02 | 2.0 % | $ 110 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
3.06 M | $ 3.2 | 1.03 % | $ 45 M | USA |
 |
Cronos Group
CRON
|
-176 M | $ 2.57 | 1.58 % | $ 1.33 B | Canada |
 |
Catalent
CTLT
|
-260 M | - | - | $ 11.5 B | USA |
 |
Emergent BioSolutions
EBS
|
-601 M | $ 8.19 | -0.49 % | $ 419 M | USA |
 |
Evolus
EOLS
|
-25.2 M | $ 4.08 | 1.24 % | $ 263 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Harrow Health
HROW
|
31.8 M | $ 35.64 | 0.92 % | $ 1.31 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.49 | 1.45 % | $ 86.3 M | Canada |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.4 | 1.44 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
12.3 M | $ 2.28 | 1.79 % | $ 300 M | USA |
 |
Pacira BioSciences
PCRX
|
5.41 M | $ 22.78 | 0.35 % | $ 1.05 B | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 6.92 | -1.0 % | $ 273 M | USA |
 |
Rockwell Medical
RMTI
|
-2.5 M | $ 0.91 | -4.84 % | $ 32.7 M | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.88 | -0.35 % | $ 43.9 M | USA |
 |
Solid Biosciences
SLDB
|
-178 M | $ 7.56 | 0.93 % | $ 662 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.38 | 1.1 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.57 M | $ 2.36 | -0.42 % | $ 2.93 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 6.71 | 2.37 % | $ 4.15 B | Canada |
 |
Veru
VERU
|
-36.6 M | $ 2.34 | 2.18 % | $ 316 M | USA |
 |
Viatris
VTRS
|
3.51 B | $ 13.35 | -0.71 % | $ 16 B | USA |
 |
Jupiter Wellness
JUPW
|
654 K | - | - | $ 33.6 M | USA |
 |
cbdMD
YCBD
|
-2.86 M | $ 0.73 | - | $ 3.15 M | USA |
 |
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-100 M | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
-22.3 M | - | - | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
28.3 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-1.74 M | $ 0.63 | - | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.01 M | $ 2.01 | 0.5 % | $ 23.3 M | USA |